• OPEN AN ACCOUNT
Indian Indices
Sensex
78,542.44 43.27
( 0.06%)
Global Indices
Nasdaq
54,056.75 150.65
(0.28%)
Dow Jones
7,778.11 47.15
(0.61%)
Hang Seng
66,870.65 1,263.94
(1.93%)
Nikkei 225
10,909.12 41.23
(0.38%)
Forex
USD-INR
95.20 0.13
(0.14%)
EUR-INR
109.83 0.08
(0.08%)
GBP-INR
128.13 0.14
(0.11%)
JPY-INR
0.60 0.00
(-0.12%)

EQUITY - MARKET SCREENER

Birla Corporation Ltd
Industry :  Cement - North India
BSE Code
ISIN Demat
Book Value()
500335
INE340A01012
623.4605895
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
BIRLACORPN
28.7
7043.33
EPS(TTM)
Face Value()
Div & Yield %
31.87
10
1.37
 

cress&a solutions ltd
USFDA inspects Cipla subsidiary's manufacturing unit in New York
Jul 18,2026

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).

The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.